172 related articles for article (PubMed ID: 16386625)
1. Contamination of the nebulization systems used in the prophylaxis with amphotericin B nebulized in lung transplantation.
Monforte V; Román A; Gavaldà J; Bravo C; Rodriguez V; Ferrer A; Pahissa A; Morell F
Transplant Proc; 2005 Nov; 37(9):4056-8. PubMed ID: 16386625
[TBL] [Abstract][Full Text] [Related]
2. Microbial contamination of nebulizers in the home treatment of cystic fibrosis.
Blau H; Mussaffi H; Mei Zahav M; Prais D; Livne M; Czitron BM; Cohen HA
Child Care Health Dev; 2007 Jul; 33(4):491-5. PubMed ID: 17584406
[TBL] [Abstract][Full Text] [Related]
3. A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting.
O'Malley CA; VandenBranden SL; Zheng XT; Polito AM; McColley SA
Respir Care; 2007 Mar; 52(3):258-62. PubMed ID: 17328823
[TBL] [Abstract][Full Text] [Related]
4. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety.
Monforte V; Ussetti P; López R; Gavaldà J; Bravo C; de Pablo A; Pou L; Pahissa A; Morell F; Román A
J Heart Lung Transplant; 2009 Feb; 28(2):170-5. PubMed ID: 19201343
[TBL] [Abstract][Full Text] [Related]
5. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
[TBL] [Abstract][Full Text] [Related]
6. Bacterial Surface Detachment during Nebulization with Contaminated Reusable Home Nebulizers.
Harris JC; Collins MS; Huang PH; Schramm CM; Nero T; Yan J; Murray TS
Microbiol Spectr; 2022 Feb; 10(1):e0253521. PubMed ID: 35107362
[TBL] [Abstract][Full Text] [Related]
7. Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis.
Vassal S; Taamma R; Marty N; Sardet A; d'athis P; Brémont F; Dalphin ML; Plésiat P; Rault G; Thubert J; Dominique S; Lemeland JF; Derelle J; Blech MF; Roussey M; Perrin M; Sautegeau A
Am J Infect Control; 2000 Oct; 28(5):347-51. PubMed ID: 11029133
[TBL] [Abstract][Full Text] [Related]
8. [Problems in the use, cleaning and maintenance of nebulization equipment in the home situation].
Struycken VH; Tiddens HA; van den Broek ET; Dzoljic-Danilovic G; van der Velden AJ; de Jongste JC
Ned Tijdschr Geneeskd; 1996 Mar; 140(12):654-8. PubMed ID: 8668238
[TBL] [Abstract][Full Text] [Related]
9. Nebulizers in cystic fibrosis: a source of bacterial contamination in cystic fibrosis patients?
Brzezinski LX; Riedi CA; Kussek P; Souza HH; Rosário N
J Bras Pneumol; 2011; 37(3):341-7. PubMed ID: 21755189
[TBL] [Abstract][Full Text] [Related]
10. Low level of bacterial contamination of mist tents used in home treatment of cystic fibrosis patients.
Jakobsson B; Hjelte L; Nyström B
J Hosp Infect; 2000 Jan; 44(1):37-41. PubMed ID: 10633052
[TBL] [Abstract][Full Text] [Related]
11. Microbial contamination of home nebulizers in children with cystic fibrosis and clinical implication on the number of pulmonary exacerbations.
Tabatabaii SA; Khanbabaee G; Sadr S; Farahbakhsh N; Aghdam MK; Lotfollahzadeh S; Hosseini A; Dara N; Nanbakhsh M; Gorji FA
BMC Pulm Med; 2020 Feb; 20(1):33. PubMed ID: 32028925
[TBL] [Abstract][Full Text] [Related]
12. Aerosolized liposomal Amphotericin B: a potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients.
Kamalaporn H; Leung K; Nagel M; Kittanakom S; Calvieri B; Reithmeier RA; Coates AL
Pediatr Pulmonol; 2014 Jun; 49(6):574-80. PubMed ID: 23843366
[TBL] [Abstract][Full Text] [Related]
13. Effects of nebulized amphotericin B and budesonide inhalation for chronic cough-related laryngeal sensations.
Ogawa H; Fujimura M; Ohkura N; Makimura K
Auris Nasus Larynx; 2015 Jun; 42(3):221-5. PubMed ID: 25466805
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant.
Monforte V; López-Sánchez A; Zurbano F; Ussetti P; Solé A; Casals C; Cifrian J; de Pablos A; Bravo C; Román A
J Heart Lung Transplant; 2013 Mar; 32(3):313-9. PubMed ID: 23332731
[TBL] [Abstract][Full Text] [Related]
15. Effect that an educational program for cystic fibrosis patients and caregivers has on the contamination of home nebulizers.
Della Zuana A; Garcia Dde O; Juliani RC; Silva Filho LV
J Bras Pneumol; 2014; 40(2):119-27. PubMed ID: 24831395
[TBL] [Abstract][Full Text] [Related]
16. Impact of hypochlorite-based disinfection on bacterial contamination of cystic fibrosis patients' home-nebulisers.
Reychler G; Leonard A; Van Ossel C; Godding V; Gigi J; Simon A; Lebecque P
J Hosp Infect; 2009 Aug; 72(4):351-7. PubMed ID: 19596489
[TBL] [Abstract][Full Text] [Related]
17. [Anti-infective aerosols].
Diot P; Dequin PF; Rivoire B; Gagnadoux F; Faurisson F; Diot E; Boissinot E; Lemarié E
Rev Mal Respir; 1999 Jun; 16(3):277-85. PubMed ID: 10472633
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
[TBL] [Abstract][Full Text] [Related]
19. Nebulizer use and maintenance by cystic fibrosis patients: a survey study.
Lester MK; Flume PA; Gray SL; Anderson D; Bowman CM
Respir Care; 2004 Dec; 49(12):1504-8. PubMed ID: 15571641
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B disposition after aerosol inhalation in lung transplant recipients.
Marra F; Partovi N; Wasan KM; Kwong EH; Ensom MH; Cassidy SM; Fradet G; Levy RD
Ann Pharmacother; 2002 Jan; 36(1):46-51. PubMed ID: 11816256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
